Navigation Links
Threshold Pharmaceuticals Announces Two Presentations on Glufosfamide at the 2007 European Cancer Conference (ECCO)
Date:9/6/2007

Detailed Data from the Phase 3 Glufosfamide and Phase 2 Glufosfamide Plus

Gemcitabine Clinical Trials to be Presented

REDWOOD CITY, Calif., Sept. 6 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD), today announced two presentations regarding its oncology product candidate glufosfamide. The presentations will take place at the 2007 European Cancer Conference (ECCO) being held September 23 to 27, 2007, at the International Conference Center in Barcelona, Spain.

As announced on February 26, 2007, the Phase 3 trial of glufosfamide showed that the overall survival in patients with metastatic pancreatic cancer who had relapsed after gemcitabine chemotherapy was 18% higher in the glufosfamide arm compared to those who received best supportive care (BSC), but the result did not reach statistical significance. Detailed analysis of the data from that study suggests that glufosfamide is active in certain subgroups of patients. The Company believes that additional clinical investigation of these subgroups is warranted. These data and subgroups will be described during the oral presentation on September 27.

The following oral presentation will take place:

Glufosfamide (GLU) in metastatic pancreatic adenocarcinoma previously treated with gemcitabine: Results of a Phase 3 trial.

Gastrointestinal malignancies -- noncolorectal cancer, Room 111 Thursday, September 27, 2007 at 10:15am

As announced on December 27, 2006, the response rate for the Phase 2 glufosfamide plus gemcitabine front-line pancreatic cancer trial was 21% (including one unconfirmed partial response). The detailed results of the Phase 2 trial, including complete 12-month survival data, will be presented during a poster presentation on September 26.

The following poster presentation will take place:

Glufosfamide (GLU) plus gemcitabine (GEM) in pancreatic adenocarcinoma: Results of a Phase 2 trial.

Gastrointestinal malignancies -- noncolorectal cancer, Level 0 Wednesday, September 26, 2007 from 9:00am to 12:00pm

A copy of the Phase 3 abstract will be available on the Threshold website on September 27. A copy of the Phase 2 poster and abstract will be available on the website on September 26 at http://investor.thresholdpharm.com/calendar.cfm.

About Threshold Pharmaceuticals

Threshold is a biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer. By selectively targeting abnormally-proliferating tumor cells, the Company's drug candidates are designed to be potentially more effective and less toxic to healthy tissues than conventional treatments. For additional

information, please visit our website (http://www.thresholdpharm.com).

Forward-Looking Statements

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding Threshold's product candidates, and potential therapeutic uses and benefits of our product candidates. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, Threshold's ability to commence its anticipated clinical trials, the time and expense required to conduct such clinical trials and analyze data, issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results). Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on August 7, 2007 and is available from the SEC's website (http://www.sec.gov) and on our website (http://www.thresholdpharm.com) under the heading "Investors." We do not intend to update any forward-looking statement made in this news release.

Contact:

Denise T. Powell

Sr. Director, Corporate Communications

Threshold Pharmaceuticals, Inc.

650-474-8206,

dpowell@thresholdpharm.com


'/>"/>
SOURCE Threshold Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Threshold Pharmaceuticals Announces Multiple Presentations on Oncology Pipeline at the 2007 American Association for Cancer Research (AACR) Annual Meeting
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2017)... March 30, 2017  Purcell Julie & Lefkowitz LLP, a ... investigating a potential breach of fiduciary duty claim involving the ... SGYP ). If you are a shareholder ... regarding this investigation, free of charge, please visit us at: ... ...
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 Research ... Chromatograph Market 2017-2021" report to their offering. ... The global gas chromatograph market ... The report, Global Gas Chromatograph Market 2017-2021, has ... industry experts. The report covers the market landscape and its growth ...
(Date:3/29/2017)... Mar. 29, 2017 Research and Markets has announced ... Proton Therapy Centers & Forecast" report to their offering. ... Proton Therapy Market in ... market value in 2016. There are currently three proton therapy centers in ... treat more patients. In Italy , the first patients ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 2017 , ... Full Contact K9, an Atlanta-based dog services provider, has recently ... assists dog owners in creating legally-enforceable pet trusts for their canine companions. , ... to protect their new companion. Says Evan Dunbar, CEO of Full Contact K9, “When ...
(Date:3/29/2017)... FL (PRWEB) , ... March 30, 2017 , ... Sublime ... the "Spice of Life" or "Wonder Spice", it has been used for thousands of ... in the East," says Heshelow, author of " Turmeric: How to Use it For ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wall Centre Dental team ... patients from Burnaby, BC. Patients in need of experienced orthodontics, laser dentistry, porcelain ... the esteemed team at Wall Centre Dental. Drs. Parviz Roshan, Siamak Tehrani, Milton ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... (GRMA) is growing as it continues developing an ANSI-approved, consensus-based American National ... organization, which plans to publish the first ANSI-approved GMP standard for dietary ...
(Date:3/29/2017)... ... 2017 , ... An inventor from Raynham, Mass., knows the ... conjunction with my braces always rubbed against the inside of my cheeks, causing ... problem." The O.B.S. was the result of his brainstorming. , This patent-pending invention ...
Breaking Medicine News(10 mins):